|Bid||225.79 x 100|
|Ask||232.86 x 100|
|Day's Range||227.07 - 231.62|
|52 Week Range||184.50 - 256.80|
|PE Ratio (TTM)||7.10|
|Dividend & Yield||2.80 (1.20%)|
|1y Target Est||N/A|
Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.
A Goldman spokesman said that the firm believes the case is 'without merit' and that they will 'vigorously contest it.'
The complaint also blasts Goldman for having few blacks in leadership positions.